Search

Researchers from UC San Diego, the J. Craig Venter Institute and Yale University have been awarded $10 million by the Howard Hughes Medical Institute (HHMI) to support research on using jumbo viruses as new therapeutic agents.

Vésale Bioscience, a Belgian phage therapy company, has been awarded a €1.8m grant from the European Innovation Council to develop a phage therapy diagnostic platform to fight multidrug-resistant infections.

Ben Chan (Center for Phage Biology & Therapy, Yale University) and colleagues report the use of a personalized, inhaled phage therapy for treating P. aeruginosa infections in 9 CF adults, with the goal of selecting phages that target bacter

The UK Parliament's Science and Technology Committee has launched an inquiry into the antimicrobial potential of bacteriophages as a way to address antibiotic resistance. Here you can read 34 public letters contributed by the international

We are urgently seeking Corynebacterium striatum phages for patient with a prosthetic joint infection in the USA. Ways to help at this stage: - By sending your phages for testing on the patient's strains - By receiving one or more of the

We are urgently seeking Corynebacterium striatum phages for patient with a prosthetic joint infection in the USA. Ways to help at this stage: - By sending your phages for testing on the patient's strains - By receiving one or more of the

Baylor College of Medicine (Houston, TX) is hiring a Research Technician III to join TAILOR Labs, whose objective is to study the molecular and clinical properties of phage to advance the knowledge of phage therapy and phage biology.

Vesale Bioscience is hiring a Production Manager to be responsible for the development, organization, and optimization of the phage production, and to work with the Queen Astrid Military Hospital to ensure the connection between the two pro

A lab at Jichi Medical University is hiring a postdoc interested in the field of microbiome, bacteriophage (phage engineering, development of phage-based therapeutic agents, bacterial gene detection reagents, vaccines, etc.), as well as in

The 6th World Congress on Targeting Phage Therapy 2023 will be held on June 1-2, 2023 in Paris, France. The aim of the meeting is to discuss all aspects related to phages and phage therapy. We will highlight the recent innovations and clini

The Phage Innovation Network will be launched by Innovate UK Knowledge Transfer Network on Feb 16 2023 with an online event. This network is designed to bring together those in the UK with an interest in bacteriophages, their use and applic

Registration is now open for An Unfinished Life: AMR Awareness Australia: In collaboration with organizations across Australia, Diane Shader Smith and Richard Alm of CARB-X are hosting a multi day, multi city, multi speaker event to premier

Swapnil Ganesh Sanmukh (Institute for Bioengineering of Catalonia) and colleagues published a new paper in MDPI Cells on accessing the in vivo efficiency of clinically isolated phages against uropathogenic and invasive biofilm-forming Esche

Joshua D Jones (University of Edinburgh) and colleagues authored a new perspective on why patients should not be transferred between healthcare jurisdictions for phage therapy in the UK.

The Phage Innovation Network will be launched by Innovate UK Knowledge Transfer Network on Feb 16 2023 with an online event. This network is designed to bring together those in the UK with an interest in bacteriophages, their use and applic

We are urgently seeking Pseudomonas aeruginosa phages for a patient in Portugal. Ways to help at this stage: - By sending your phages for testing on the patient's strains - By receiving one or more of the patient's strains and testing you

We are urgently seeking Pseudomonas aeruginosa phages for a patient in Portugal. Ways to help at this stage: - By sending your phages for testing on the patient's strains - By receiving one or more of the patient's strains and testing you

Steffanie Strathdee, Graham Hatfull, Vivek Mutalik and Robert Schooley wrote a new review of the state of the art in phage therapy, covering biological mechanisms, clinical applications, remaining challenges, and future directions.

The Antibacterial Resistance Leadership Group will begin a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial to examine safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized

From 2018 to 2022, IPATH initiated phage hunts for 265 patients, but 25% couldn't proceed due to lack of phages. IPATH has now partnered with Korean phage company MicrobiotiX; IPATH will screen and send sample isolates to MicrobiotiX, who w